Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $48,425 | 12 | 43.3% |
| Unspecified | $45,233 | 11 | 40.5% |
| Food and Beverage | $9,936 | 398 | 8.9% |
| Travel and Lodging | $4,775 | 22 | 4.3% |
| Honoraria | $2,000 | 1 | 1.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1,300 | 1 | 1.2% |
| Education | $111.95 | 4 | 0.1% |
Payments by Type
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Galderma Laboratories, L.P. | $78,609 | 129 | $0 (2024) |
| Bausch Health US, LLC | $7,328 | 3 | $0 (2021) |
| Ipsen Innovation | $4,505 | 3 | $0 (2020) |
| STRATA Skin Sciences, Inc. | $4,041 | 3 | $0 (2023) |
| DERMIRA, INC. | $3,081 | 9 | $0 (2020) |
| Almirall LLC | $2,817 | 11 | $0 (2024) |
| PFIZER INC. | $2,172 | 30 | $0 (2024) |
| Sensus Healthcare, Inc. | $2,107 | 2 | $0 (2018) |
| Valeant Pharmaceuticals North America LLC | $1,440 | 2 | $0 (2017) |
| MAYNE PHARMA INC. | $1,003 | 76 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $39,631 | 53 | Galderma Laboratories, L.P. ($38,580) |
| 2023 | $37,279 | 90 | Galderma Laboratories, L.P. ($30,294) |
| 2022 | $987.33 | 31 | Galderma Laboratories, L.P. ($364.41) |
| 2021 | $10,403 | 45 | Bausch Health US, LLC ($7,328) |
| 2020 | $7,416 | 36 | Ipsen Innovation ($4,505) |
| 2019 | $3,530 | 29 | DERMIRA, INC. ($3,012) |
| 2018 | $9,975 | 90 | Galderma Laboratories, L.P. ($4,404) |
| 2017 | $2,561 | 75 | Valeant Pharmaceuticals North America LLC ($1,440) |
All Payment Transactions
449 individual payment records from CMS Open Payments — Page 1 of 18
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/20/2024 | Journey Medical Corporation | — | Food and Beverage | In-kind items and services | $24.06 | General |
| 11/13/2024 | Galderma Laboratories, L.P. | — | Consulting Fee | Cash or cash equivalent | $1,700.00 | General |
| 11/08/2024 | Galderma Laboratories, L.P. | — | — | Cash or cash equivalent | $690.80 | Research |
| Study: 43BBJ1911 | ||||||
| 11/08/2024 | Galderma Laboratories, L.P. | — | Food and Beverage | In-kind items and services | $9.58 | General |
| 10/26/2024 | Galderma Laboratories, L.P. | — | Food and Beverage | In-kind items and services | $157.56 | General |
| 10/23/2024 | Ortho Dermatologics, a division of Bausch Health US, LLC | Cabtreo (Drug), JUBLIA | Food and Beverage | In-kind items and services | $20.22 | General |
| Category: Dermatology | ||||||
| 10/19/2024 | MAYNE PHARMA COMMERCIAL LLC | — | Food and Beverage | In-kind items and services | $4.04 | General |
| 10/18/2024 | MAYNE PHARMA COMMERCIAL LLC | — | Food and Beverage | In-kind items and services | $9.52 | General |
| 10/01/2024 | Incyte Corporation | OPZELURA (Drug) | Food and Beverage | Cash or cash equivalent | $28.19 | General |
| Category: Dermatology | ||||||
| 09/17/2024 | REVANCE THERAPEUTICS, INC. | DAXXIFY (Drug) | Food and Beverage | In-kind items and services | $15.25 | General |
| Category: AESTHETICS AND THERAPEUTICS | ||||||
| 09/13/2024 | Galderma Laboratories, L.P. | — | — | Cash or cash equivalent | $5,852.00 | Research |
| Study: 43BBJ1911 | ||||||
| 09/09/2024 | SUN PHARMACEUTICAL INDUSTRIES INC. | BLU-U (Medical Supply), Odomzo | Food and Beverage | In-kind items and services | $28.23 | General |
| Category: Dermatology | ||||||
| 08/29/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $25.32 | General |
| Category: Immunology | ||||||
| 08/28/2024 | Galderma Laboratories, L.P. | DYSPORT (Biological) | Food and Beverage | In-kind items and services | $11.28 | General |
| 08/28/2024 | Galderma Laboratories, L.P. | DYSPORT (Biological) | Food and Beverage | In-kind items and services | $0.98 | General |
| 08/16/2024 | Galderma Laboratories, L.P. | — | — | Cash or cash equivalent | $10,566.80 | Research |
| Study: 43BBJ1911 | ||||||
| 08/09/2024 | REVANCE THERAPEUTICS, INC. | DAXXIFY (Drug) | Food and Beverage | In-kind items and services | $23.65 | General |
| Category: AESTHETICS AND THERAPEUTICS | ||||||
| 07/31/2024 | MAYNE PHARMA COMMERCIAL LLC | — | Food and Beverage | In-kind items and services | $9.28 | General |
| 07/16/2024 | Galderma Laboratories, L.P. | — | Food and Beverage | In-kind items and services | $3.33 | General |
| 07/12/2024 | Galderma Laboratories, L.P. | — | — | Cash or cash equivalent | $2,307.20 | Research |
| Study: 43BBJ1911 | ||||||
| 06/21/2024 | Galderma Laboratories, L.P. | — | — | Cash or cash equivalent | $12,580.20 | Research |
| Study: 43BBJ1911 | ||||||
| 06/19/2024 | MAYNE PHARMA COMMERCIAL LLC | — | Food and Beverage | In-kind items and services | $8.85 | General |
| 05/23/2024 | REVANCE THERAPEUTICS, INC. | DAXXIFY (Drug) | Food and Beverage | In-kind items and services | $26.20 | General |
| Category: AESTHETICS AND THERAPEUTICS | ||||||
| 05/22/2024 | Galderma Laboratories, L.P. | — | Food and Beverage | In-kind items and services | $18.27 | General |
| 05/16/2024 | ABBVIE INC. | — | Food and Beverage | In-kind items and services | $150.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| 43BBJ1911 | Galderma Laboratories, L.P. | $36,411 | 6 |
| A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE CONTROLLED, PARALLEL-GROUP, CLINICAL STUDY COMPARING THE EFFICACY AND SAFETY OF IDP-126 GEL IN THE TREATMENT OF ACNE VULGARIS | Bausch Health US, LLC | $7,283 | 2 |
| A Phase 3, Multi-Center, Randomized, Double-Blind, Vehicle-Controlled, 2-Arm, Parallel Group Comparison Study Comparing the Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris | Valeant Pharmaceuticals North America LLC | $1,440 | 2 |
| A LONG-TERM STUDY TO ASSESS THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | Eli Lilly and Company | $99.59 | 1 |
About Dr. Glynis Ablon, M.D
Dr. Glynis Ablon, M.D is a Dermatology healthcare provider based in Manhattan Beach, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/06/2006. The National Provider Identifier (NPI) number assigned to this provider is 1144292889.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Glynis Ablon, M.D has received a total of $111,781 in payments from pharmaceutical and medical device companies, with $39,631 received in 2024. These payments were reported across 449 transactions from 39 companies. The most common payment nature is "Consulting Fee" ($48,425).
Practice Information
- Specialty Dermatology
- Location Manhattan Beach, CA
- Active Since 02/06/2006
- Last Updated 02/19/2008
- Taxonomy Code 207N00000X
- Entity Type Individual
- NPI Number 1144292889
Products in Payments
- DYSPORT (Drug) $4,505
- XTRAC (Device) $4,041
- QBREXZA (Drug) $3,055
- LITFULO (Drug) $1,595
- DORYX (Drug) $788.11
- Xeomin (Biological) $690.64
- EUCRISA (Drug) $476.56
- ENSTILAR (Drug) $322.05
- OPZELURA (Drug) $280.17
- TREMFYA (Drug) $202.90
- FABIOR (Drug) $179.25
- Ecoza (Drug) $135.28
- JUBLIA (Drug) $129.73
- Seysara (Drug) $126.34
- Winlevi (Drug) $121.22
- AKLIEF (Drug) $116.56
- CLODERM (Drug) $115.07
- ORACEA (Drug) $109.70
- XEOMIN (Biological) $107.37
- COSENTYX (Drug) $104.06
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Dermatology Doctors in Manhattan Beach
Dr. Ashley Magovern, M.d, M.D
Dermatology — Payments: $50,946
Dr. Nina Desai, M.d, M.D
Dermatology — Payments: $15,110
Dr. Scott Rackett, M.d, M.D
Dermatology — Payments: $14,011
Dr. Nicole Salame, Md, MD
Dermatology — Payments: $3,206
Dr. Jamie Macdougall, Md, MD
Dermatology — Payments: $485.13
Meagan Hughes, M.d, M.D
Dermatology — Payments: $413.60